Innovus Pharma Files Its Product License Application for Commercialization of EjectDelay™ for Premature Ejaculation in Canada

Published: Oct 29, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LA JOLLA, Calif., Oct. 29, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") (OTCBB:INNV), today announced that the Company filed its Product License Application with Health Canada to market its premature ejaculation topical treatment EjectDelayTM. EjectDelayTM has the active drug Benzocaine and works by blocking the sodium channels of the nerves and therefore temporarily desensitizing the glans of the penis allowing longer ejaculatory time. If accepted by Health Canada, EjectDelayTM will be available as a 7.5% strength in 2oz over-the-counter gel and will not require a prescription. The product is not expected to be reimbursed by the Canadian government, therefore, the Company will be able to set the retail price through its potential commercial partners.

Help employers find you! Check out all the jobs and post your resume.

Back to news